Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 21Genitourinary 7Breast 5NET 4Endocrine 4Other 3Gynecologic 3Thoracic 2Sarcoma 2Plasma cell 2Dermatologic 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5760Lung Neoplasms 3725Small Cell Lung Carcinoma 1021Breast Neoplasms 668Neoplasms 615Colorectal Neoplasms 562Melanoma 479Ovarian Neoplasms 435Neoplasm Metastasis 432Pancreatic Neoplasms 387Stomach Neoplasms 332Carcinoma, Renal Cell 312Adenocarcinoma of Lung 309Squamous Cell Carcinoma of Head and Neck 306Head and Neck Neoplasms 295Prostatic Neoplasms 285Mesothelioma, Malignant 281Esophageal Neoplasms 266Mesothelioma 244Colonic Neoplasms 226Brain Neoplasms 217Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 212Uterine Cervical Neoplasms 209Endometrial Neoplasms 175Sarcoma 172Carcinoma, Hepatocellular 159NSCLC 136Carcinoma 128Kidney Neoplasms 127

Interventions

Theophylline 1Loperamide 1Fecal Microbiota Transplantation 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Diarrhea × Thoracic × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

NCT02080078 2019-05-03

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

AHS Cancer Control Alberta

Phase 1 Terminated
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Diarrhea

Data powered by HemOnc (CC BY 4.0) Colophon âš¡